ZymoGenetics ZGEN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ZymoGenetics ZGEN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: idos who wrote (148)	10/27/2008 12:54:18 PM
From: tuck	Read Replies (1) of 210

Meanwhile atacicept stumbles a bit, causing ZGEN to firesale and test all time lows. >>27-Oct-2008 Regulation FD Disclosure Item 7.01. Regulation FD Disclosure. On October 27, 2008, Merck Serono announced that it was discontinuing the study in lupus nephritis in the ongoing Phase II/III systemic lupus erythematosus (SLE) atacicept program. The study combining mycophenolate mofetil, corticosteroids and atacicept in patients with kidney disease had been initiated in December 2007. The observation of an increased risk for severe infection led to the discontinuation. This observation was likely the result of the underlying significant disease activity and the concomitant use of several immunosuppressive medications. The ongoing atacicept programs in generalized SLE, rheumatoid arthritis, multiple sclerosis and hematological malignancies are continuing.<< What would be the difference between generalized SLE and SLE? Or are they the same, and the company is saying that other trials with different protocols are ongoing in the same indication? TIA & Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next